Gravar-mail: A3 A PROOF-OF-CONCEPT, PHASE 2 CLINICAL TRIAL OF THE GI SAFETY OF A HYDROGEN SULFIDE-RELEASING ANTI-INFLAMMATORY DRUG (ATB-346)